Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES

Affiliations

• ¹ Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA.
• ² CPC Clinical Research, Aurora, CO, USA and State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA.
• ³ Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, Leiden, the Netherlands.
• ⁴ Université Paris-Cité, INSERM-UMR1148, F-75018, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and Institut Universitaire de France, Paris, France.
• ⁵ Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands and Netherlands Heart Institute, Utrecht, the Netherlands.
• ⁶ Roche Diagnostics International AG, Zug, Switzerland.
• ⁷ Mount Sinai Heart, Icahn School of Medicine at Mount Sinai Health System, New York, NY, USA.
• ⁸ Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA.
• ⁹ Estudios Cardiológicos Latino América, Instituto Cardiovascular de Rosario, Rosario, Argentina.
• ¹⁰ Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
• ¹¹ Sanofi, Ontario, Canada.
• ¹² Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada and St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
• ¹³ Weill Cornell Medicine, New York, NY, USA.
• ¹⁴ Green Lane Cardiovascular Research Unit, Te Whatu Ora - Health New Zealand, Te Toka Tumai, and University of Auckland, Auckland, New Zealand.
• ¹⁵ Department of Medicine III, Goethe University, Frankfurt am Main, Germany.